User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.

Primary tabs

download
  • Open access
  • PDF
  • 1.14 M
Tuyaerts, Sandra Van Nuffel, An M T Naert, Eline Van Dam, Peter A Vuylsteke, Peter [UCL] Denys, Hannelore

(eng) BACKGROUND: Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13-17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tumor vasculature. In other malignancies, combining checkpoint blockade with radiation delivers benefit that is believed to be due to the abscopal effect. Addition of immune modulation agents has also shown to enhance immune checkpoint blockade efficacy. Therefore we designed a regimen consisting of PD-1 blockade combined with radiation, and different immune/environmental-targeting compounds: repurposed drugs, metronomic chemotherapy and a food supplement. We hypothesize that these will synergistically modulate the tumor microenvironment and induce and sustain an anti-tumor immune response, resulting in tumor regression. METHODS: PRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma. Treatment consists of daily intake of vitamin D, lansoprazole, aspirin, cyclophosphamide and curcumin, starting 2 weeks before the first pembrolizumab dose. Pembrolizumab is administered 3-weekly for a total of 6 cycles. Radiation (3 × 8 Gy) is given on days 1, 3 and 5 of the first pembrolizumab dose. The safety run-in consists of 6 patients. In total, 18 and 25 evaluable patients for cervical and endometrial carcinoma respectively are foreseen to enroll. No sample size is determined for uterine sarcoma due to its rarity. The primary objective is objective response rate at week 26 according to immune-related response criteria. Secondary objectives include safety, objective response rate at week 26 according to RECIST v1.1, best overall response, progression-free survival, overall survival and quality of life. Exploratory, translational research aims to evaluate immune biomarkers, extracellular vesicles, cell death biomarkers and the gut microbiome. DISCUSSION: In this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational research is performed to discover biomarkers related to the mode of action of the combination. TRIAL REGISTRATION: EU Clinical Trials Register: EudraCT 2016-001569-97 , registered on 19-6-2017. Clinicaltrials.gov: NCT03192059 , registered on 19-6-2017.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2019
Language Anglais
Journal information "BMC cancer" - Vol. 19, no. 1, p. 506 [1-10] (2019)
Peer reviewed yes
Publisher BioMed Central Ltd ((United Kingdom) London)
e-issn 1471-2407
Publication status Publié
Affiliations UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Service d'oncologie médicale
Keywords Cervical carcinoma ; Drug repurposing ; Endometrial carcinoma ; Financial toxicity ; Immune modulation ; Metronomic chemotherapy ; PD-1 blockade ; Radiation ; Tumor microenvironment ; Uterine sarcoma
Links
  1. Torre Lindsey A., Bray Freddie, Siegel Rebecca L., Ferlay Jacques, Lortet-Tieulent Joannie, Jemal Ahmedin, Global cancer statistics, 2012 : Global Cancer Statistics, 2012, 10.3322/caac.21262
  2. Marth C., Landoni F., Mahner S., McCormack M., Gonzalez-Martin A., Colombo N., Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, 10.1093/annonc/mdx220
  3. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/archive/csr/1975_2013/ , based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
  4. zur Hausen Harald, Papillomaviruses in the causation of human cancers — a brief historical account, 10.1016/j.virol.2008.11.046
  5. Chung Hyun Cheol, Schellens Jan H. M., Delord Jean-Pierre, Perets Ruth, Italiano Antoine, Shapira-Frommer Ronnie, Manzuk Lyudmila, Piha-Paul Sarina Anne, Wang Jiangdian, Zeigenfuss Susan, Pruitt Scott K., Marabelle Aurelien, Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study., 10.1200/jco.2018.36.15_suppl.5522
  6. Ferlay Jacques, Soerjomataram Isabelle, Dikshit Rajesh, Eser Sultan, Mathers Colin, Rebelo Marise, Parkin Donald Maxwell, Forman David, Bray Freddie, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 : Globocan 2012, 10.1002/ijc.29210
  7. Salani Ritu, Backes Floor J., Fung Kee Fung Michael, Holschneider Christine H., Parker Lynn P., Bristow Robert E., Goff Barbara A., Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations, 10.1016/j.ajog.2011.03.008
  8. Garg G, Mutch DG. Treatment Strategies and Prognosis of Endometrial Cancer. In: Saldivar JS, editor. Cancer of the Uterine Endometrium - Advances and Controversies. London: InTech; 2012. Available from: https://www.intechopen.com/books/cancer-of-the-uterine-endometrium-advances-and-controversies/treatment-strategies-and-prognosis-in-endometrial-cancer .
  9. Eggink Florine A., Van Gool Inge C., Leary Alexandra, Pollock Pamela M., Crosbie Emma J., Mileshkin Linda, Jordanova Ekaterina S., Adam Julien, Freeman-Mills Luke, Church David N., Creutzberg Carien L., De Bruyn Marco, Nijman Hans W., Bosse Tjalling, Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition, 10.1080/2162402x.2016.1264565
  10. Howitt Brooke E., Shukla Sachet A., Sholl Lynette M., Ritterhouse Lauren L., Watkins Jaclyn C., Rodig Scott, Stover Elizabeth, Strickland Kyle C., D’Andrea Alan D., Wu Catherine J., Matulonis Ursula A., Konstantinopoulos Panagiotis A., Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1, 10.1001/jamaoncol.2015.2151
  11. van Gool I. C., Eggink F. A., Freeman-Mills L., Stelloo E., Marchi E., de Bruyn M., Palles C., Nout R. A., de Kroon C. D., Osse E. M., Klenerman P., Creutzberg C. L., Tomlinson I. P. M., Smit V. T. H. B. M., Nijman H. W., Bosse T., Church D. N., POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer, 10.1158/1078-0432.ccr-15-0057
  12. Santin A. D., Bellone S., Buza N., Choi J., Schwartz P. E., Schlessinger J., Lifton R. P., Regression of Chemotherapy-Resistant Polymerase   (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab, 10.1158/1078-0432.ccr-16-1031
  13. Mehnert Janice M., Panda Anshuman, Zhong Hua, Hirshfield Kim, Damare Sherri, Lane Katherine, Sokol Levi, Stein Mark N., Rodriguez-Rodriquez Lorna, Kaufman Howard L., Ali Siraj, Ross Jeffrey S., Pavlick Dean C., Bhanot Gyan, White Eileen P., DiPaola Robert S., Lovell Ann, Cheng Jonathan, Ganesan Shridar, Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer, 10.1172/jci84940
  14. Chern JY, Boyd LR, Blank SV. Uterine sarcomas: the latest approaches for these rare but potentially deadly tumors. Oncology (Williston Park). 2017;31:229–36.
  15. Cuppens Tine, Depreeuw Jeroen, Annibali Daniela, Thomas Debby, Hermans Els, Gommé Ellen, Trinh Xuan Bich, Debruyne David, Moerman Philippe, Lambrechts Diether, Amant Frédéric, Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models, 10.1016/j.ygyno.2017.06.005
  16. Paoluzzi L., Cacavio A., Ghesani M., Karambelkar A., Rapkiewicz A., Weber J., Rosen G., Response to anti-PD1 therapy with nivolumab in metastatic sarcomas, 10.1186/s13569-016-0064-0
  17. George Suzanne, Miao Diana, Demetri George D., Adeegbe Dennis, Rodig Scott J., Shukla Sachet, Lipschitz Mikel, Amin-Mansour Ali, Raut Chandrajit P., Carter Scott L., Hammerman Peter, Freeman Gordon J., Wu Catherine J., Ott Patrick A., Wong Kwok-Kin, Van Allen Eliezer M., Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma, 10.1016/j.immuni.2017.02.001
  18. Ben-Ami Eytan, Barysauskas Constance M., Solomon Sarah, Tahlil Kadija, Malley Rita, Hohos Melissa, Polson Kathleen, Loucks Margaret, Severgnini Mariano, Patel Tara, Cunningham Amy, Rodig Scott J., Hodi F. Stephen, Morgan Jeffrey A., Merriam Priscilla, Wagner Andrew J., Shapiro Geoffrey I., George Suzanne, Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study : Nivolumab for Uterine Leiomyosarcoma, 10.1002/cncr.30738
  19. Tumeh Paul C., Harview Christina L., Yearley Jennifer H., Shintaku I. Peter, Taylor Emma J. M., Robert Lidia, Chmielowski Bartosz, Spasic Marko, Henry Gina, Ciobanu Voicu, West Alisha N., Carmona Manuel, Kivork Christine, Seja Elizabeth, Cherry Grace, Gutierrez Antonio J., Grogan Tristan R., Mateus Christine, Tomasic Gorana, Glaspy John A., Emerson Ryan O., Robins Harlan, Pierce Robert H., Elashoff David A., Robert Caroline, Ribas Antoni, PD-1 blockade induces responses by inhibiting adaptive immune resistance, 10.1038/nature13954
  20. Smyth Mark J., Ngiow Shin Foong, Ribas Antoni, Teng Michele W. L., Combination cancer immunotherapies tailored to the tumour microenvironment, 10.1038/nrclinonc.2015.209
  21. Luke Jason J., Lemons Jeffrey M., Karrison Theodore G., Pitroda Sean P., Melotek James M., Zha Yuanyuan, Al-Hallaq Hania A., Arina Ainhoa, Khodarev Nikolai N., Janisch Linda, Chang Paul, Patel Jyoti D., Fleming Gini F., Moroney John, Sharma Manish R., White Julia R., Ratain Mark J., Gajewski Thomas F., Weichselbaum Ralph R., Chmura Steven J., Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors, 10.1200/jco.2017.76.2229
  22. Kroeze Stephanie G.C., Fritz Corinna, Hoyer Morten, Lo Simon S., Ricardi Umberto, Sahgal Arjun, Stahel Rolf, Stupp Roger, Guckenberger Matthias, Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review, 10.1016/j.ctrv.2016.11.013
  23. Teng Feifei, Kong Li, Meng Xiangjiao, Yang Jia, Yu Jinming, Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges, 10.1016/j.canlet.2015.05.012
  24. Dovedi Simon J., Adlard Amy L., Lipowska-Bhalla Grazyna, McKenna Conor, Jones Sherrie, Cheadle Eleanor J., Stratford Ian J., Poon Edmund, Morrow Michelle, Stewart Ross, Jones Hazel, Wilkinson Robert W., Honeychurch Jamie, Illidge Tim M., Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade, 10.1158/0008-5472.can-14-1258
  25. Vatner Ralph E., Cooper Benjamin T., Vanpouille-Box Claire, Demaria Sandra, Formenti Silvia C., Combinations of Immunotherapy and Radiation in Cancer Therapy, 10.3389/fonc.2014.00325
  26. Ahmed M. M., Hodge J. W., Guha C., Bernhard E. J., Vikram B., Coleman C. N., Harnessing the Potential of Radiation-Induced Immune Modulation for Cancer Therapy, 10.1158/2326-6066.cir-13-0141
  27. Barker Holly E., Paget James T. E., Khan Aadil A., Harrington Kevin J., The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence, 10.1038/nrc3958
  28. Zhuravel E, Efanova O, Shestakova T, Glushko N, Mezhuev O, Soldatkina M, Pogrebnoy P. Administration of vitamin D3 improves antimetastatic efficacy of cancer vaccine therapy of Lewis lung carcinoma. Exp Oncol. 2010;32:33–9.
  29. Walsh Jarrett E., Clark Anna-Maria, Day Terry A., Gillespie M. Boyd, Young M. Rita I., Use of α,25-Dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma, 10.1016/j.humimm.2010.04.008
  30. Kulbersh Jonathan S., Day Terry A., Gillespie M. Boyd, Young M. Rita I., 1α,25-Dihydroxyvitamin D3 to skew intratumoral levels of immune inhibitory CD34+ progenitor cells into dendritic cells, 10.1016/j.otohns.2008.11.011
  31. Lathers Deanne M. R., Clark Joseph I., Achille Nicholas J., Young M. Rita I., Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D 3, 10.1007/s00262-003-0459-7
  32. Lathers Deanne M.R., Clark Joseph I., Achille Nicholas J., Young M.Rita I., Phase IB study of 25-hydroxyvitamin D3 treatment to diminish suppressor cells in head and neck cancer patients, 10.1016/s0198-8859(01)00317-2
  33. So Jae Young, Suh Nanjoo, Targeting cancer stem cells in solid tumors by vitamin D, 10.1016/j.jsbmb.2014.10.007
  34. Jeong Y., Swami S., Krishnan A. V., Williams J. D., Martin S., Horst R. L., Albertelli M. A., Feldman B. J., Feldman D., Diehn M., Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D, 10.1158/1535-7163.mct-15-0066
  35. Liao Zhongxing, Mason Kathryn A, Milas Luka, Cyclo-Oxygenase-2 and its Inhibition in Cancer : Is There a Role?, 10.2165/00003495-200767060-00001
  36. Zelenay Santiago, van der Veen Annemarthe G., Böttcher Jan P., Snelgrove Kathryn J., Rogers Neil, Acton Sophie E., Chakravarty Probir, Girotti Maria Romina, Marais Richard, Quezada Sergio A., Sahai Erik, Reis e Sousa Caetano, Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity, 10.1016/j.cell.2015.08.015
  37. Hamada T, Giannakis M, Ogino S. Aspirin in the era of immunotherapy. Oncotarget. 2017;8:73370–1.
  38. Holmes Chris E., Jasielec Jagoda, Levis Jamie E., Skelly Joan, Muss Hyman B., Initiation of Aspirin Therapy Modulates Angiogenic Protein Levels in Women with Breast Cancer Receiving Tamoxifen Therapy : Aspirin Modifies Platelet Angiogenic Proteins, 10.1111/cts.12070
  39. Corbet Cyril, Feron Olivier, Tumour acidosis: from the passenger to the driver's seat, 10.1038/nrc.2017.77
  40. Lu Zhen-Ning, Tian Bing, Guo Xiu-Li, Repositioning of proton pump inhibitors in cancer therapy, 10.1007/s00280-017-3426-2
  41. Bellone Matteo, Calcinotto Arianna, Filipazzi Paola, De Milito Angelo, Fais Stefano, Rivoltini Licia, The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors, 10.4161/onci.22058
  42. Calcinotto A., Filipazzi P., Grioni M., Iero M., De Milito A., Ricupito A., Cova A., Canese R., Jachetti E., Rossetti M., Huber V., Parmiani G., Generoso L., Santinami M., Borghi M., Fais S., Bellone M., Rivoltini L., Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes, 10.1158/0008-5472.can-11-1272
  43. Penel Nicolas, Adenis Antoine, Bocci Guido, Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?, 10.1016/j.critrevonc.2011.04.009
  44. Sistigu Antonella, Viaud Sophie, Chaput Nathalie, Bracci Laura, Proietti Enrico, Zitvogel Laurence, Immunomodulatory effects of cyclophosphamide and implementations for vaccine design, 10.1007/s00281-011-0245-0
  45. Scurr Martin, Pembroke Tom, Bloom Anja, Roberts David, Thomson Amanda, Smart Kathryn, Bridgeman Hayley, Adams Richard, Brewster Alison, Jones Robert, Gwynne Sarah, Blount Daniel, Harrop Richard, Hills Robert, Gallimore Awen, Godkin Andrew, Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer, 10.1158/1078-0432.ccr-17-0895
  46. Shehzad Adeeb, Park Jeen-Woo, Lee Jaetae, Lee Young Sup, Curcumin induces radiosensitivity of in vitro and in vivo cancer models by modulating pre-mRNA processing factor 4 (Prp4), 10.1016/j.cbi.2013.10.007
  47. Basnet Purusotam, Skalko-Basnet Natasa, Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer Treatment, 10.3390/molecules16064567
  48. Lim Seung-Oe, Li Chia-Wei, Xia Weiya, Cha Jong-Ho, Chan Li-Chuan, Wu Yun, Chang Shih-Shin, Lin Wan-Chi, Hsu Jung-Mao, Hsu Yi-Hsin, Kim Taewan, Chang Wei-Chao, Hsu Jennifer L., Yamaguchi Hirohito, Ding Qingqing, Wang Yan, Yang Yi, Chen Chung-Hsuan, Sahin Aysegul A., Yu Dihua, Hortobagyi Gabriel N., Hung Mien-Chie, Deubiquitination and Stabilization of PD-L1 by CSN5, 10.1016/j.ccell.2016.10.010
  49. Prasad Vinay, De Jesús Kevin, Mailankody Sham, The high price of anticancer drugs: origins, implications, barriers, solutions, 10.1038/nrclinonc.2017.31
  50. Kaiser Jocelyn, Too much of a good thing?, 10.1126/science.359.6382.1346
  51. Mailankody Sham, Prasad Vinay, Five Years of Cancer Drug Approvals : Innovation, Efficacy, and Costs, 10.1001/jamaoncol.2015.0373
  52. van Harten Wim H, Wind Anke, de Paoli Paolo, Saghatchian Mahasti, Oberst Simon, Actual costs of cancer drugs in 15 European countries, 10.1016/s1470-2045(15)00486-6
  53. Kantarjian Hagop, Steensma David, Rius Sanjuan Judit, Elshaug Adam, Light Donald, High Cancer Drug Prices in the United States: Reasons and Proposed Solutions, 10.1200/jop.2013.001351
Bibliographic reference Tuyaerts, Sandra ; Van Nuffel, An M T ; Naert, Eline ; Van Dam, Peter A ; Vuylsteke, Peter ; et. al. PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.. In: BMC cancer, Vol. 19, no. 1, p. 506 [1-10] (2019)
Permanent URL http://hdl.handle.net/2078.1/217895